From: N6-Methyladenosine RNA modification in cerebrospinal fluid as a novel potential diagnostic biomarker for progressive multiple sclerosis
Training (n = 41)
Test (n = 20)
P
Age (years)
45.0 ± 14.5
44.7 ± 18.2
0.954
Female (%)
26 (63.4%)
11 (55%)
0.528
Diagnosis (%)
 RRMS
21 (51.2%)
11 (55.0%)
0.959
 SPMS
13 (31.7%)
6 (30.0%)
 PPMS
7 (17.1%)
3 (15.0%)